#United States #New York #Class Action #Pomerantz LLP #Nektar Therapeutics

Overview of the Class Action Against Nektar Therapeutics

In recent news, Pomerantz LLP, a recognized leader in securities class action litigation, has filed a significant class action lawsuit against Nektar Therapeutics, Inc. (NASDAQ: NKTR) and certain executives. This legal action, which began in the United States District Court for the Northern District of California, highlights substantial allegations regarding violations of federal securities laws. The case is officially listed under docket number 26-cv-01951.

Who is Affected?

The class action lawsuit represents a group of investors who purchased or acquired securities of Nektar Therapeutics during the period from February 26, 2025, through December 15, 2025. During this time, investors are asserting that the company's actions and statements misled them, leading to a loss of their investments. Those impacted have until May 5, 2026, to come forward and request appointment as Lead Plaintiff in the lawsuit. To facilitate participation, interested parties can visit Pomerantz Law Firm's website for further details regarding the complaint and their rights.

The Allegations in Detail

According to the complaint, Nektar Therapeutics is accused of making materially false and misleading statements throughout the class period. Specifically, the lawsuit claims that the company's disclosures regarding its leading product candidate, rezpegaldesleukin (also known as REZPEG or NKTR-358), were deceptive. Rezpegaldesleukin is aiming to treat autoimmune disorders, particularly alopecia areata.

In March 2024, Nektar initiated the Phase 2b REZOLVE-AA trial, which aimed to evaluate rezpegaldesleukin in patients suffering from severe alopecia areata. However, despite official communication indicating that the enrollment proceeded according to protocol, the complaint alleges that this was not the case.

Key misrepresentations include assertions that the trial's enrollment met regulatory and protocol standards, while in reality, significant discrepancies existed. Furthermore, it suggests that the integrity of the trial—and therefore the efficacy and expected outcomes of the drug—was overstated, misleading investors about the reality of the situation.

Emergence of Truth and Aftermath

The truth about the trial and its results started to surface on December 16, 2025. Nektar sent out a press release revealing that the trial had not produced statistically significant outcomes. This was attributed to the incorrect inclusion of four patients who were not eligible. As a result of this news, Nektar's stock price took a significant hit, plummeting $4.14 or 7.77%, closing at $49.16 per share.

Such a drastic decline in stock value highlights the serious implications of the alleged misconduct by Nektar's executives. Investors are understandably upset, as the firm’s earlier promises appeared to have been made without a basis in truth, leading to substantial financial losses.

About Pomerantz LLP

Pomerantz LLP is esteemed in securities class actions and has a long history of representing investors in cases of securities fraud and corporate misconduct. Established over 85 years ago, the firm continues to uphold its commitment to protecting the rights of its clients. With a proven track record in recovering significant compensation for class members, the firm remains a pivotal player in the legal landscape.

How to Inquire Further

Investors seeking more information on this class action can reach out to Danielle Peyton at Pomerantz LLP at the provided contact details, where inquiries can be made confidentially and appropriately directed. Inquiries via email are encouraged to include the investor's mailing address and contact information for timely responses.

Conclusion

This case serves as a reminder of the importance of transparency and ethical conduct in corporate governance. As legal proceedings unfold, the implications for Nektar Therapeutics and its shareholders will be closely watched. Investors may consider participation in the ongoing legal process to seek redress for potential losses incurred due to the alleged misconduct surrounding the REZOLVE-AA trial.

Investors thought to have been impacted should not hesitate to act, as the window to join as Lead Plaintiff is limited. Pomerantz LLP remains ready to assist affected parties navigate this complex situation.